mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months.

Tande, Aaron J; Pollock, Benjamin D; Shah, Nilay D; Binnicker, Matthew; Berbari, Elie F

Tande, Aaron J; Pollock, Benjamin D; Shah, Nilay D; Binnicker, Matthew; Berbari, Elie F.

Tande AJ; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
Pollock BD; Department of Quality, Experience, and Affordability, Mayo Clinic, Rochester, Minnesota.
Shah ND; Division of Health Care Delivery Research, Robert D. and Patricia E, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
Binnicker M; Delta Air Lines, Atlanta, Georgia.
Berbari EF; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Infect Control Hosp Epidemiol ; 43(3): 393-395, 2022 03.

Article in English | MEDLINE | ID: covidwho-1598564

Subject(s)

COVID-19; SARS-CoV-2; COVID-19/prevention & control; Humans; RNA, Messenger; Vaccines, Synthetic; mRNA Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Infect Control Hosp Epidemiol Journal subject: Communicable Diseases / Nursing / Epidemiology / Hospitals Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google